862 related articles for article (PubMed ID: 35783879)
1. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
Fargion S; Porzio M; Fracanzani AL
World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
[TBL] [Abstract][Full Text] [Related]
3. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
[TBL] [Abstract][Full Text] [Related]
4. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
Choudhary NS; Duseja A
J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
[TBL] [Abstract][Full Text] [Related]
5. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
Oni ET; Agatston AS; Blaha MJ; Fialkow J; Cury R; Sposito A; Erbel R; Blankstein R; Feldman T; Al-Mallah MH; Santos RD; Budoff MJ; Nasir K
Atherosclerosis; 2013 Oct; 230(2):258-67. PubMed ID: 24075754
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
[TBL] [Abstract][Full Text] [Related]
8. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
9. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.
Pacifico L; Nobili V; Anania C; Verdecchia P; Chiesa C
World J Gastroenterol; 2011 Jul; 17(26):3082-91. PubMed ID: 21912450
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association.
Bali AD; Rosenzveig A; Frishman WH; Aronow WS
Cardiol Rev; 2023 Feb; ():. PubMed ID: 36825899
[TBL] [Abstract][Full Text] [Related]
11. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
Duseja A; Singh SP; Saraswat VA; Acharya SK; Chawla YK; Chowdhury S; Dhiman RK; Jayakumar RV; Madan K; Misra SP; Mishra H; Modi SK; Muruganathan A; Saboo B; Sahay R; Upadhyay R
J Clin Exp Hepatol; 2015 Mar; 5(1):51-68. PubMed ID: 25941433
[TBL] [Abstract][Full Text] [Related]
15. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
16. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
17. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
18. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R;
Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496
[TBL] [Abstract][Full Text] [Related]
19. Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients.
Shao C; Ye J; Li F; Lin Y; Wu T; Wang W; Feng S; Zhong B
Dig Dis Sci; 2020 Jun; 65(6):1850-1860. PubMed ID: 31724099
[TBL] [Abstract][Full Text] [Related]
20. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]